Rewalk Robotics (RWLK) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research cut shares of Rewalk Robotics (NASDAQ:RWLK) from a buy rating to a hold rating in a report released on Thursday morning.

According to Zacks, “ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company’s exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. “

Separately, Oppenheimer set a $2.00 target price on shares of Rewalk Robotics and gave the company a buy rating in a research report on Friday, August 24th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $2.38.



Shares of Rewalk Robotics stock opened at $0.72 on Thursday. Rewalk Robotics has a 52-week low of $0.70 and a 52-week high of $1.60.

Rewalk Robotics (NASDAQ:RWLK) last announced its earnings results on Tuesday, August 14th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. The company had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $1.90 million. Rewalk Robotics had a negative net margin of 365.87% and a negative return on equity of 3,654.32%. As a group, equities analysts forecast that Rewalk Robotics will post -0.67 EPS for the current fiscal year.

About Rewalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.

Recommended Story: What kind of dividend yield to CEF’s pay?

Get a free copy of the Zacks research report on Rewalk Robotics (RWLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Rewalk Robotics (NASDAQ:RWLK)

Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply